Nivolumab in previously untreated melanoma without BRAF mutation.

@article{Robert2015NivolumabIP,
  title={Nivolumab in previously untreated melanoma without BRAF mutation.},
  author={C Melville Robert and Georgina V. Long and Benjamin M. R Brady and Caroline Dutriaux and Michele Maio and Laurent Mortier and Jessica C Hassel and Piotr Łukasz Rutkowski and Toni K Choueiri and Piotr Rutkowski and Kerry J. Savage and Micaela M Hernberg and Celeste Lebb{\'e} and J. W. Brooks Charles and Catalin Mihalcioiu and Vanna Chiarion-Sileni and Cornelia Mauch and Francesco Cognetti and Ana M Arance and Henrik Nikolaj Blicher Schmidt and Dirk Schadendorf and Helen J. Gogas and Lotta Lundgren-Eriksson and Christine E. Horak and Brian Sharkey and Ian M. Waxman and Victoria Atkinson and Paolo Antonio Ascierto},
  journal={The New England journal of medicine},
  year={2015},
  volume={372 4},
  pages={
          320-30
        }
}
BACKGROUND Nivolumab was associated with higher rates of objective response than chemotherapy in a phase 3 study involving patients with ipilimumab-refractory metastatic melanoma. The use of nivolumab in previously untreated patients with advanced melanoma has not been tested in a phase 3 controlled study. METHODS We randomly assigned 418 previously untreated patients who had metastatic melanoma without a BRAF mutation to receive nivolumab (at a dose of 3 mg per kilogram of body weight every… CONTINUE READING

Citations

Publications citing this paper.
SHOWING 1-10 OF 1,389 CITATIONS

A Cost-Effectiveness Analysis of Nivolumab Compared with Ipilimumab for the Treatment of BRAF Wild-Type Advanced Melanoma in Australia.

  • Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
  • 2016
VIEW 12 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

Current state of anti-PD-L1 and anti-PD-1 agents in cancer therapy.

VIEW 6 EXCERPTS
CITES BACKGROUND & RESULTS
HIGHLY INFLUENCED

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer

  • The Journal of experimental medicine
  • 2019
VIEW 9 EXCERPTS
CITES BACKGROUND & METHODS
HIGHLY INFLUENCED

A Serum Protein Signature Associated with Outcome after Anti-PD-1 Therapy in Metastatic Melanoma.

  • Cancer immunology research
  • 2018
VIEW 5 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

Immune Checkpoint Inhibitor Therapy in Breast Cancer.

  • Journal of the National Comprehensive Cancer Network : JNCCN
  • 2018
VIEW 8 EXCERPTS
CITES BACKGROUND
HIGHLY INFLUENCED

FILTER CITATIONS BY YEAR

2013
2019

CITATION STATISTICS

  • 74 Highly Influenced Citations

  • Averaged 371 Citations per year over the last 3 years

References

Publications referenced by this paper.
SHOWING 1-10 OF 23 REFERENCES

Treatment algorithms in stage IV melanoma.

Enrique Espinosa, Jean-Jacques Grob, +8 authors Dirk Schadendorf
  • American journal of therapeutics
  • 2015

Efficacy and safety of the anti-PD-1 monoclonal antibody MK-3475 in 411 patients (pts) with melanoma (MEL)

A Ribas, SF Hodi, R Kefford
  • J Clin Oncol 2014;32:Suppl:5s. abstract
  • 2014

Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab.

  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2014

Similar Papers

Loading similar papers…